◀ Back to EGFR

EGFR — TP53

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: TP53 → EGFR (decreases)
  Evidence: In addition, immunohistochemical analysis showed that the expression of wild-type p53 was significantly increased in the antisense-EGFR cDNA transfected clones,
• WikiPathways Gastric Cancer Network 2: TP53 → EGFR (activation)

Text-mined interactions from Literome

Sun et al., Mol Carcinog 1999 (Neoplasm Metastasis) : p53 transcriptionally activates expression of the genes encoding epidermal growth factor receptor , matrix metalloproteinase (MMP)-2, cathepsin D, and thrombospondin-1 but represses expression of the genes encoding basic fibroblast growth factor and multidrug resistance-1
Halatsch et al., Anticancer Res 2001 (Glioblastoma) : This study sought to investigate whether overexpression of deletion-mutant ( delta ) EGFR affects genotoxic stress provoked mRNA inductions of p53 and murine double minute 2 (MDM2), two other genes strongly involved in the pathogenesis of GBM
Lin et al., Cancer Res 2002 (Breast Neoplasms) : Expression of wt p53 did not cause a reduction in the phosphorylation of three unrelated protein kinases in other signal transduction pathways, AKT, extracellular signal regulated kinase ( ERK ) 1, and ERK2 or a reduction of phosphorylation of epidermal growth factor receptor
Purow et al., Carcinogenesis 2008 (Brain Neoplasms...) : Experiments with p53 positive and -null cell lines confirmed that p53 partially mediates the effects of Notch-1 on EGFR expression
Bheda et al., Oncogene 2008 : Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes ... Exogenous wild-type p53 inhibits the EGFR promoter at low levels, and activates it at higher concentrations ... Wild-type p53 suppressed Sp1- and YY1 mediated induction of the EGFR promoter
Nie et al., Mol Cancer Ther 2008 (Colonic Neoplasms...) : AAV-HGFK1+Ad-p53 also inhibited tumor cell growth in vitro by inhibiting epidermal growth factor receptor phosphorylation
Rieber et al., Int J Cancer 2009 (Breast Neoplasms...) : Since the p53 tumor suppressor pathway is inactivated in most human cancers due to gene mutations or defective wt p53 signaling, we now investigated in human wt p53 breast carcinoma MCF-7 cells, whether single treatment with the p53 transactivation pharmacological inhibitor pifithrin-alpha, transient p53 siRNA interference or stable insertion of a dominant negative ( DN ) R175H p53 mutant increase : ( i ) EGFR/erbB1 activation , ( ii ) MMP-9 expression and ( iii ) loss of surface E-cadherin
Klanrit et al., Oncogene 2009 (Head and Neck Neoplasms) : p53 activates EGFR expression, whereas TAp63 represses EGFR transcription
Muller et al., Cell 2009 (Neoplasm Metastasis) : These activities of p53 reflect enhanced integrin and epidermal growth factor receptor (EGFR) trafficking, which depends on Rab coupling protein (RCP) and results in constitutive activation of EGFR/integrin signaling
Sauer et al., Oncogene 2010 (MAP Kinase Signaling System...) : Finally, p53 may further regulate this feedback loop by altering the level of EGFR expression
Watt et al., J Neurooncol 2010 (Glioma) : This was in agreement with the fact that p53 activation did not induce Bax upregulation nor did EGFR inhibition promote Bad dephosphorylation
Deb et al., Oncogene 1994 : Wild-type human p53 activates the human epidermal growth factor receptor promoter ... We propose that p53 successfully nucleates the transcription complex, possibly via direct interaction with TFIID, and activates the EGFR promoter
Ludes-Meyers et al., Mol Cell Biol 1996 : Transcriptional activation of the human epidermal growth factor receptor promoter by human p53 ... The human epidermal growth factor receptor (EGFR) promoter is activated by both wild-type and tumor derived mutant p53 ... We further show that the EGFR promoter is also activated by tumor derived p53 mutants p53-143A, p53-175H, p53-248W, p53-273H, and p53-281G ... The minimal EGFR promoter from positions -- 104 to -- 20 which does not contain the wild-type p53 binding site is transactivated by the p53 mutants but not by the wild-type protein, showing a difference in the mechanism of transactivation by wild-type and mutant p53 ... Transactivation of the EGFR promoter by p53 may represent a novel mechanism of cell growth regulation
Sheikh et al., Oncogene 1997 (Breast Neoplasms) : We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status ... Wild-type and mutant p53Ala143 enhanced the EGF-R core promotor activity in cells that were either p53-deficient or contained wild-type or mutant endogenous p53